A Phase 1 interventional study of Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria) and Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA) in Healthy, sponsored by Sandoz. Completed. Open to participants aged 18 Years to 56 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by Sandoz · Phase 1, Interventional, and Treatment
To demonstrate the relative bioequivalence of Cefdinir and Omnicel 250mg/5 ml fasting conditions.
Sandoz is the lead sponsor of 136 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
Drug: Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
Drug: Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
Bioequivalence based on AUC and Cmax
Time frame: 10 days
No study locations are listed for this record.
This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sandoz